Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Psoriatic Arthritis Treatment Market Forecast: What Market Value Is Expected By 2030?
The psoriatic arthritis treatment market has experienced notable expansion over the past few years. Projected to climb from $13.17 billion in 2025 to $14.36 billion in 2026, it is anticipated to achieve a compound annual growth rate (CAGR) of 9.0%. This historical growth has been driven by several factors, including restricted access to advanced treatment options, heavy dependence on traditional NSAIDs and DMARDs, a rising incidence of psoriatic arthritis, heightened awareness among patients, and the broadening of hospital and retail pharmacy networks.
The market for psoriatic arthritis treatments is set to undergo substantial expansion in the coming years, reaching an estimated $20.62 billion by 2030 with a compound annual growth rate (CAGR) of 9.5%. This projected growth during the forecast period is driven by factors such as the advancement of interleukin and JAK inhibitors, a rising reliance on biologic therapies, the emergence of personalized medicine, increased use of telemedicine for managing chronic conditions, and heightened financial backing from governments and insurers. Key trends shaping this period include the growing acceptance of biologics and targeted synthetic DMARDs, a greater focus on early detection and management of psoriatic arthritis, the development of tailored treatments addressing both joint and skin manifestations, an expanded reach through hospital and specialized pharmacy channels, and the incorporation of telehealth along with remote patient monitoring.
Download A Free Sample Report For Comprehensive Market Insights:
Psoriatic Arthritis Treatment Market Growth Drivers And Industry Catalysts
The expected rise in healthcare spending is set to drive forward the expansion of the psoriatic arthritis treatment market in the coming period. Healthcare spending, which can also be referred to as healthcare expenditure, involves the financial resources that are directed toward supporting the delivery of medical services, products, and programs within a given country, region, or healthcare framework. This funding aids the diagnostic process by covering the costs associated with medical consultations, laboratory tests, and imaging procedures that are needed for accurate disease identification. For individuals with PsA, a detailed assessment is frequently conducted to confirm the diagnosis, evaluate the degree of joint damage, and identify any coexisting health conditions that may be present. As an example, data from December 2024 provided by the Centers for Medicare & Medicaid Services, a U.S. agency responsible for overseeing the Medicare and Medicaid programs, indicated that healthcare expenditures in the United States rose by 7.5% in 2023, reaching $4.9 trillion, which equates to approximately $14,570 per person. Consequently, this growth in healthcare spending is stimulating the advancement of the psoriatic arthritis treatment market.
Psoriatic Arthritis Treatment Market Segments: Where Are The Largest Growth Opportunities?
The psoriatic arthritis treatment market covered in this report is segmented –
1) By Drug Class: Nonsteroidal Anti-Inflammatory Drugs (NSAIDS), Disease-Modifying Anti-Rheumatic Drugs (DMARDS), Biologics, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Topical
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Subsegments:
1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, COX-2 Inhibitors
2) By Disease-Modifying Anti-Rheumatic Drugs (DMARDs): Conventional DMARDs, Targeted Synthetic DMARDs
3) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors, Other Biologics
4) By Other Drug Classes: Corticosteroids, Topical Treatments, Janus Kinase (JAK) Inhibitors
Psoriatic Arthritis Treatment Market Trends Influencing Long-Term Demand
Major pharmaceutical players in the psoriatic arthritis treatment sector are securing approvals for new therapies, including Cosentyx, as a strategy to enhance their market profitability. Cosentyx is prescribed for autoimmune disorders such as non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and enthesitis-related arthritis. For example, in October 2023, the Switzerland-based company Novartis reported that the Food and Drug Administration had granted approval for their novel drug, Cosentyx. This medication operates as a human interleukin-17A antagonist, working to inhibit the activity of the IL-17A protein, which in turn minimizes potential adverse effects in patients, including swelling, discomfort, and skin rashes. Clinical evidence demonstrates that Cosentyx effectively alleviates psoriatic arthritis symptoms, with some patients noticing improvement within just three weeks. The drug addresses multiple manifestations of the condition, such as joint pain and tenderness, back discomfort, and dermatological issues.
Psoriatic Arthritis Treatment Market Major Participants And Competitive Dynamics
Major companies operating in the psoriatic arthritis treatment market are AbbVie Inc., Amgen Astellas BioPharma K.K., Johnson & Johnson Services Inc., Bristol-Myers Squibb Company, Celgene Corporation, Novartis International AG, Eli Lilly and Company, Pfizer Inc., Merck & Co. Inc., AstraZeneca plc, Sanofi SA, Otsuka Pharmaceutical Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Bayer AG, Eisai Inc., Janssen Pharmaceuticals Inc., Gilead Sciences Inc., GlaxoSmithKline plc, Regeneron Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Chugai Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd.
Access The Complete Psoriatic Arthritis Treatment Market Report:
Psoriatic Arthritis Treatment Market Regional Outlook: Where Are The Largest Opportunities Located?
North America was the largest region in the psoriatic arthritis treatment market in 2025. The regions covered in the psoriatic arthritis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model